261 related articles for article (PubMed ID: 8303305)
1. The gene therapy of cancer: transgenic immunotherapy.
Zwiebel JA; Su N; MacPherson A; Davis T; Ojeifo JO
Semin Hematol; 1993 Oct; 30(4 Suppl 4):119-28; discussion 129. PubMed ID: 8303305
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
3. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
4. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
5. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
6. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
7. Combining radiation therapy with interleukin-3 gene immunotherapy.
Chiang CS; Hong JH; Wu YC; McBride WH; Dougherty GJ
Cancer Gene Ther; 2000 Aug; 7(8):1172-8. PubMed ID: 10975678
[TBL] [Abstract][Full Text] [Related]
8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
9. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunogene therapy.
Yoshizawa H; Kagamu H; Gejyo F
Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
[TBL] [Abstract][Full Text] [Related]
11. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
13. Gene transfer approaches in cancer immunotherapy.
Larin SS; Georgiev GP; Kiselev SL
Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
15. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of tumor metastasis via gene therapy.
Porgador A; Feldman M; Eisenbach L
Nat Immun; 1994; 13(2-3):113-30. PubMed ID: 8173233
[TBL] [Abstract][Full Text] [Related]
17. Molecular approaches to cancer immunotherapy.
Forni G; Cavallo F; Consalvo M; Allione A; Dellabona P; Casorati G; Giovarelli M
Cytokines Mol Ther; 1995 Dec; 1(4):225-48. PubMed ID: 9384678
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models.
Tüting T; Gambotto A; Baar J; Davis ID; Storkus WJ; Zavodny PJ; Narula S; Tahara H; Robbins PD; Lotze MT
Gene Ther; 1997 Oct; 4(10):1053-60. PubMed ID: 9415311
[TBL] [Abstract][Full Text] [Related]
19. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
20. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
Fernandez N; Duffour MT; Perricaudet M; Lotze MT; Tursz T; Zitvogel L
Cytokines Cell Mol Ther; 1998 Mar; 4(1):53-65. PubMed ID: 9557217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]